Related Disease - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of historical and ...

B-cell depletion with inebilizumab reduced flare risk for pancreatic and/or biliary IgG4-related disease. It also reduced overall glucocorticoid use for disease control in both groups. SAN DIEGO ...

Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, ...

Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.

Inebilizumab (Uplizna) treatment significantly reduced the risk of flares in patients who had IgG4-related disease (IgG4-RD) with involvement in the pancreas, bile ducts, or liver, according to a ...

US FDA grants orphan drug designation to Sanofi’s rilzabrutinib to treat sickle cell disease: Paris Thursday, June 5, 2025, 11:00 Hrs [IST] The US Food and Drug Administration ( ...

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseasesUnder regulatory review in the US, the EU, and China in ...

Sanofi announced today that the U.S. FDA has granted orphan drug designation to rilzabrutinib for the treatment of sickle ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.